AbbVie FY 2024: revenue $56.3B, up 4%; diluted EPS $2.39

Key figures from this report

These are the numbers AbbVie reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$56.3B+4% from $54.3B in FY 202310-K income statement, on EDGAR
2. Net income$4.3B−12% from $4.9B in FY 202310-K income statement, on EDGAR
3. Diluted EPS$2.39−12% from $2.72 in FY 202310-K income statement, on EDGAR
4. Cash and cash equivalents$5.5B−57% from $12.8B in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$18.8B−18% from $22.8B in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables